Translational Preclinical Pharmacologic Disease Models for Ophthalmic Drug Development

Mihir Shah,Sara Cabrera-Ghayouri,Lori-Ann Christie,Katherine S. Held,Veena Viswanath

DOI: https://doi.org/10.1007/s11095-019-2588-5

IF: 4.58

2019-02-25

Pharmaceutical Research

Abstract:ABSTRACT Preclinical models of human diseases are critical to our understanding of disease etiology, pathology, and progression and enable the development of effective treatments. An ideal model of human disease should capture anatomical features and pathophysiological mechanisms, mimic the progression pattern, and should be amenable to evaluating translational endpoints and treatment approaches. Preclinical animal models have been developed for a variety of human ophthalmological diseases to mirror disease mechanisms, location of the affected region in the eye and severity. These models offer clues to aid in our fundamental understanding of disease pathogenesis and enable progression of new therapies to clinical development by providing an opportunity to gain proof of concept (POC). Here, we review preclinical animal models associated with development of new therapies for diseases of the ocular surface, glaucoma, presbyopia, and retinal diseases, including diabetic retinopathy and age-related macular degeneration (AMD). We have focused on summarizing the models critical to new drug development and described the translational features of the models that contributed to our understanding of disease pathogenesis and establishment of preclinical POC.

pharmacology & pharmacy,chemistry, multidisciplinary